Our Network

Breakthrough discoveries rarely happen in isolation. They emerge when dynamic partnerships bring together bright minds from diverse disciplines, enabling new perspectives and collaborative problem-solving. This has never been more evident in drug discovery than now, as academia and industry work together to reshape the field at the intersection of human expertise and artificial intelligence (AI).

Blood cancers like multiple myeloma (MM), lymphoma and leukaemia present complex treatment challenges due to their diverse molecular and phenotypic characteristics. Many of these cancers are diagnosed at advanced stages and relapse is common, underscoring the need for a fundamentally reimagined approach to elevate the standards of care.

Clinical trials are foundational to the development of new medicines.